Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SOPHIA RAHMAN

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1306142955
CMS profile
684333
Location
PLANO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$396.99

19 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $390.34 18
Education $6.65 1

By paying entity

PY2023 · entire year · sorted by reported total

Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SOPHIA RAHMAN

NPI 1306142955 · CMS profile ID 684333

Allopathic & Osteopathic Physicians / Internal Medicine

PLANO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1306142955?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SOPHIA RAHMAN, NPI 1306142955, CMS profile ID 684333. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1306142955?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). SOPHIA RAHMAN, NPI 1306142955, CMS profile ID 684333. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1306142955?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
SOPHIA RAHMAN, NPI 1306142955, CMS profile ID 684333, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1306142955?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

19 matching records · $396.99 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 19 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–19 of 19.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $31.0811/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049745045 CMS
GlaxoSmithKline, LLC. $14.0011/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002974553 CMS
Lilly USA, LLC $12.5409/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032141759 CMS
Lilly USA, LLC $15.1009/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032307247 CMS
ABBVIE INC. $18.0408/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998185605 CMS
Lilly USA, LLC $16.9008/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032178261 CMS
Lilly USA, LLC $20.7706/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032351359 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $99.6606/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 983849023 CMS
Novo Nordisk Inc $14.7306/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002056215 CMS
Novo Nordisk Inc $22.9605/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002056247 CMS
Lilly USA, LLC $13.9705/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032397231 CMS
Lilly USA, LLC $17.8003/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032397223 CMS
Lilly USA, LLC $17.2803/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032178255 CMS
Lilly USA, LLC $6.6503/16/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032228393 CMS
Astellas Pharma US Inc $13.3103/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1033964885 CMS
Novo Nordisk Inc $19.7203/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002056237 CMS
AstraZeneca Pharmaceuticals LP $13.9202/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016232951 CMS
Lilly USA, LLC $11.3501/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032307239 CMS
Novo Nordisk Inc $17.2101/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002056225 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,375.72 96
PY2020 $292.22 19
PY2021 $650.64 34
PY2022 $158.24 10
PY2023 $396.99 19
PY2024 $94.56 6
PY2025 $105.64 6

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $41,990.92 22
PY2023 Principal investigator $811,614.84 35
PY2022 Principal investigator $1,323,851.35 26
PY2021 Principal investigator $630,272.09 34
PY2020 Principal investigator $503,977.28 37
PY2019 Principal investigator $9,368.25 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

37 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan, Inc. $385.00 12/15/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721312157
Principal investigator 1 Vanda Pharmaceuticals Inc. $66,507.35 12/09/2020 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735129081
Principal investigator 1 Vanda Pharmaceuticals Inc. $7,090.97 12/09/2020 Non-covered Recipient Entity
CLINRX RESEARCH LLC
SINGLE-PATIENT EXPANDED ACCESS PROTOCOL FOR TRADIPITANT IN A SINGLE PATIENT WITH GASTROPARESIS No dispute reported 06/30/2026 735129091
Principal investigator 1 Vanda Pharmaceuticals Inc. $59.54 11/24/2020 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735128859
Principal investigator 1 Vanda Pharmaceuticals Inc. $352.47 11/18/2020 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735128767
Principal investigator 1 Vanda Pharmaceuticals Inc. $29,449.25 11/12/2020 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735128703
Principal investigator 1 Vanda Pharmaceuticals Inc. $50,797.50 11/05/2020 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735128533
Principal investigator 1 Allergan, Inc. $115.00 10/22/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721304683
Principal investigator 1 Vanda Pharmaceuticals Inc. $50,993.50 10/07/2020 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735128209
Principal investigator 1 Allergan, Inc. $3,200.00 10/01/2020 Non-covered Recipient Entity
CLINRX RESEARCH LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721301275
Principal investigator 1 Allergan, Inc. $570.00 09/18/2020 Non-covered Recipient Entity
CLINRX RESEARCH LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721298535
Principal investigator 1 Vanda Pharmaceuticals Inc. $1,500.00 09/08/2020 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735128051
Principal investigator 1 Vanda Pharmaceuticals Inc. $29,785.00 09/08/2020 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735128057
Principal investigator 1 Allergan, Inc. $250.00 09/03/2020 Non-covered Recipient Entity
CLINRX RESEARCH LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721295399
Principal investigator 1 Vanda Pharmaceuticals Inc. $1,454.00 08/26/2020 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735127831
Principal investigator 1 Allergan, Inc. $2,144.15 08/19/2020 Non-covered Recipient Entity
CLINRX RESEARCH LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721291153
Principal investigator 1 Vanda Pharmaceuticals Inc. $43,592.25 08/17/2020 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735127721
Principal investigator 1 Allergan, Inc. $1,200.00 08/07/2020 Non-covered Recipient Entity
CLINRX RESEARCH LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721288751
Principal investigator 1 Vanda Pharmaceuticals Inc. $3,000.00 07/29/2020 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735127593
Principal investigator 1 Vanda Pharmaceuticals Inc. $482.90 07/22/2020 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735127421
Principal investigator 1 Vanda Pharmaceuticals Inc. $11,481.00 06/04/2020 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735127115
Principal investigator 1 Vanda Pharmaceuticals Inc. $1,107.49 05/13/2020 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735126771
Principal investigator 1 Vanda Pharmaceuticals Inc. $8,063.88 05/13/2020 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735126775
Principal investigator 1 Vanda Pharmaceuticals Inc. $15,998.88 05/13/2020 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735126779
Principal investigator 1 Vanda Pharmaceuticals Inc. $250.00 05/06/2020 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735126671
Principal investigator 1 Allergan, Inc. $450.00 04/27/2020 Non-covered Recipient Entity
CLINRX RESEARCH LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721272797
Principal investigator 1 Allergan, Inc. $9,000.00 04/27/2020 Non-covered Recipient Entity
CLINRX RESEARCH LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721272799
Principal investigator 1 Allergan, Inc. $32,162.25 04/20/2020 Non-covered Recipient Entity
CLINRX RESEARCH LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721271209
Principal investigator 1 Vanda Pharmaceuticals Inc. $34,325.50 04/08/2020 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735126029
Principal investigator 1 Allergan, Inc. $2,714.15 03/18/2020 Non-covered Recipient Entity
CLINRX RESEARCH LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721265423
Principal investigator 1 Vanda Pharmaceuticals Inc. $38,282.75 03/11/2020 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735125515
Principal investigator 1 Vanda Pharmaceuticals Inc. $250.00 03/11/2020 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735125517
Principal investigator 1 Allergan, Inc. $955.00 03/10/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CENICRIVIROC FOR THE TREATMENT OF LIVER FIBROSIS IN ADULT SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS. No dispute reported 06/30/2026 721262787
Principal investigator 1 Allergan, Inc. $11,400.00 02/17/2020 Non-covered Recipient Entity
CLINRX RESEARCH LLC
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 721257693
Principal investigator 1 Vanda Pharmaceuticals Inc. $24,717.00 02/05/2020 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735124849
Principal investigator 1 Vanda Pharmaceuticals Inc. $500.00 02/05/2020 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735124851
Principal investigator 1 Vanda Pharmaceuticals Inc. $19,390.50 01/09/2020 Non-covered Recipient Entity
CLINRX RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS No dispute reported 06/30/2026 735124193